BCR and acute lymphoblastic leukemia: To determine the ability of PHA-739358 to augment the efficacy of drugs currently in use in a clinical setting for therapy of Ph + ALL, we treated Pt2 cells (T315I mutation Bcr/Abl) with 2.5 nM or 5.0 nM vincristine alone or together with 1 μM PHA-739358 for 3 days.